Last reviewed · How we verify
Candesartan Cilexetil in formulation 1
At a glance
| Generic name | Candesartan Cilexetil in formulation 1 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions (PHASE1)
- Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions (PHASE1)
- Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions (PHASE1)
- A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan Cilexetil in formulation 1 CI brief — competitive landscape report
- Candesartan Cilexetil in formulation 1 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI